Drug: |
||||
---|---|---|---|---|
Trial Name: |
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 05/01/2011 |
Age of Trial (yrs) 13.6 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PI3K inhibitor + MEK inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
EMR 200066-006 |
|||
Sponsor: |
END Serono |
|||
Patient Contact: |
US Medical Information
888-275-7376
claire-helene.orsini@emdserono.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
Trial Links |
Trial Results |
Drug Information |
Name |
Address |
City |
State |
Zip |
Country |
55 Fruit Street |
Boston |
MA |
02114 |
USA |
|
8700 Beverly Blvd. |
Los Angeles |
CA |
90048 |
USA |
|
3322 West End Avenue |
Nashville |
TN |
37203 |
USA |
|
1275 York Ave |
New York |
NY |
10065 |
USA |
|
7979 Wurzbach Rd. |
San Antonio |
TX |
78229 |
USA |
|
Scottsdale |
AZ |
85258 |
USA |